



Innovating for  
affordable healthcare

## ***Shilpa Medicare Limited***

### **Corporate & Admin Office:**

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India  
Tel: +91-8532-238704, Fax: +91-8532-238876  
Email: info@vbshilpa.com, Web: www.vbshilpa.com  
CIN: L85110KA1987PLC008739

Date July 16, 2025

To,

Corporate relationship Department,  
BSE Limited,  
1<sup>st</sup> Floor, Rotunda Building  
P.J Towers Dalal Street, Fort, Mumbai 400001

National Stock Exchange of India, Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block, Bandra-Kurla Complex,  
Bandra (E), Mumbai 400051

**Stock Code: BSE – 530549 / NSE – SHILPAMED**

Dear Sir/Ma'am,

**Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

.....

### **EIR from USFDA, for Shilpa Medicare Ltd. Unit VI, Bengaluru.**

This is to inform you that Shilpa Medicare Limited, Unit VI, Dabaspeth, Bengaluru, Karnataka, India has received EIR with VAI (Voluntary Action Indicated) classification, from USFDA, for the GMP inspection which was conducted from October 24 – 30, 2024.

This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms - Oral Dissolving Films and Transdermal Systems.

The Unit is already approved by EMA, Europe; MHRA, UK; SFDA, Saudi and TGA, Australia.

This Unit is currently supplying Oral Film products to US and other markets. Transdermal products have been filed in the European market.

**For SHILPA MEDICARE LIMITED**

**Ritu Tiwary**  
**Company Secretary & Compliance Officer**